GRAIL, Inc. GRAL Screening revenue — Cost of revenue

Other product segments

Similar metrics at other companies

VCYTTesting revenue — Cost of Revenue

$33.31M+17.9%

FACost Of Services Excluding Depreciation And Amortization

$211.41M+9.8%

DGXTotal Cost of Revenue

$1.95B+9.2%

IDXXService revenue — Cost of revenue

$223.65M+12.1%

NTRAProduct revenues — Cost of revenues

$245.2M+32.8%

TEMDiagnostics — Cost of Goods Sold

$100.96M+19.1%

Questions, answered.

What is GRAIL, Inc.'s screening revenue — cost of revenue?

GRAIL, Inc. (GRAL) reported screening revenue — cost of revenue of $21.24M in Q1 2026.

How has GRAIL, Inc.'s screening revenue — cost of revenue changed year-over-year?

GRAIL, Inc.'s screening revenue — cost of revenue increased by 24.1% year-over-year, from $17.12M to $21.24M.

What is the long-term trend for GRAIL, Inc.'s screening revenue — cost of revenue?

Over 3 years (2022 to 2025), GRAIL, Inc.'s screening revenue — cost of revenue has grown at a 31.6% compound annual growth rate (CAGR), from $32.14M to $73.25M.

What does screening revenue — cost of revenue mean?

This metric captures the direct costs associated with providing diagnostic screening services, including laboratory processing, materials, and personnel directly involved in test delivery. It is a critical measure of operational efficiency and the direct expense required to generate screening-related income. Monitoring this helps assess the gross margin potential and the cost-to-serve profile of the company's diagnostic offerings.